Novo Nordisk shares slide after obesity drug trial disappoints
- Posted on December 20, 2024
- By The Times
- 4 Views
Novo Nordisk shares slide after obesity drug trial disappoints
The drug company’s market value fell by $125 billion after the trial of a new weight-loss jab missed expectations
